Bentol

Quick links to important sections

Bentol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bentol

What is Bentol? Defining the Topical Anti-Infective

Here's a quick overview of Bentol’s core identity and classification.

Property Description
Active ingredient Sulfadiazine Silver (Silver Sulfadiazine)
Form Topical Cream, Ointment, or Solution
Pharmacological class Anti-infective agent (Sulfonamide/Silver Compound)
Common use Prevention and management of wound/burn infection
Origin Synthetic Compound

What Type of Medicine is Bentol? (Identity and Classification)

Bentol is a prescription-only topical anti-infective agent containing the single active ingredient known as Sulfadiazine Silver, officially Silver Sulfadiazine. This medication is classified within the pharmacological class of a sulfonamide and a silver compound, confirming its specialized, synthetic origin. The active substance is a chemical salt developed for controlled dermal application. This compound belongs to the class of sulfonamides and is used to prevent and treat wound infections. The drug’s core function is to combat bacteria directly on the skin's surface. The compound is clinically recognized for its efficacy against a wide range of bacteria prevalent in wound environments.

Composition, Form, and General Purpose

The core of Bentol’s efficacy lies in its active component, Sulfadiazine Silver, delivered as a single active substance within a specialized topical preparation, typically a hydrophilic cream or ointment. Silver sulfadiazine is an established topical antimicrobial agent utilized in burn wound care to reduce microbial colonization. The drug's primary utility is rooted in its ability to prevent the establishment of bacterial infections in severe injuries.

The general purpose of Bentol is therefore the prevention and management of bacterial contamination in specific types of dermal injuries, such as partial-thickness burns. By employing this dual-component, broad-spectrum anti-infective action, the drug minimizes the microbial threat, which is essential for supporting the natural healing processes in specialized burn care and comprehensive wound treatment.

Regulatory References

  1. MedlinePlus

What side effects are possible with Bentol?

Possible Side Effects and Safety Information

The official safety profile of Bentol (Silver Sulfadiazine) is defined by both common local reactions and the documented potential for systemic adverse effects linked to the sulfonamide component, which may be absorbed from the treated area. The likelihood of systemic effects is tied to the percentage of the body surface area covered and the extent of tissue damage.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency and by the body system affected, according to regulatory documents.

Classification System-Organ Class Examples of Documented Effects
Common Skin, Blood Leukopenia (reversible decrease in white blood cells), burning sensation, pruritus, or rashes at the application site.
Infrequently Occurring Skin, Renal Skin necrosis, erythema multiforme, interstitial nephritis, skin discoloration.
Rare Skin Argyria (permanent bluish-gray skin discoloration).

Serious Safety Considerations

Regulatory documentation notes the potential for severe, class-specific reactions associated with systemic sulfonamide absorption. These include rare but serious adverse reactions such as severe blood dyscrasias (e.g., agranulocytosis or aplastic anemia) and life-threatening cutaneous reactions like Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).

Time-Related Safety Pattern: Leukopenia is noted to typically peak within the first two to four days following the initiation of therapy, often followed by spontaneous recovery.

Population-Specific Safety Constraints

Specific patient populations have explicit safety constraints defined in regulatory labeling:

  • Contraindicated: The medicine is contraindicated in infants less than two months old and in pregnant women nearing term due to the documented risk of kernicterus associated with sulfonamides.
  • Caution: Caution is advised for individuals with pre-existing hepatic impairment, renal impairment, or Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Overdose and Emergency Response

The official documentation defines the Bentol overdose profile based on the risk of systemic absorption of the sulfadiazine component, which primarily occurs with application to extensive burn areas or following accidental ingestion.

Systemic effects may present with clinical manifestations similar to other sulfonamides. Officially documented toxicities include specific blood dyscrasias such as leukopenia and agranulocytosis, as well as signs of liver damage (hepatotoxicity, jaundice) and kidney damage (toxic nephrosis, crystalluria). Life-threatening outcomes, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are listed severe manifestations requiring attention.

Regulators mandate that users seek immediate medical attention or call a Poison Control center right away upon suspected overdose or accidental ingestion. Management is explicitly stated to be symptomatic and supportive to enhance drug elimination, as no specific antidote is known. For extensive exposure, monitoring serum sulfa concentrations and renal function is required. The labeling contains a specific warning that the product is contraindicated in infants less than two months of age due to the risk of kernicterus.

Therapeutic Uses of Bentol

What Bentol Treats: Main Uses and Benefits

The primary therapeutic role of Bentol is focused on the specialized management of bacterial risk in severe acute dermal injuries. The medication is commonly used across domains where additional symptomatic support is needed for patients with second- and third-degree burns. This application may assist with anti-infective action to address the microbial presence that creates noticeable physiological strain in the wound.

Bentol plays a role in managing conditions where symptoms may intensify temporarily, including the acute stage of severe burns and specific types of chronic infected dermal ulcers. By controlling the bacteria, the medication may assist with reducing the potential for infectious complications.

“This benefit contributes to improved comfort during management of the patient's recovery, especially during periods of heightened symptoms.”

The medicine is considered relevant for controlling the local microbial load, which is used to reduce the likelihood of systemic infectious spread from the wound. This benefit provides support that helps ease the overall symptom burden related to infection and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Infection Risk Bentol is applied when supportive symptom management is appropriate to address microbial colonization in severe wounds, reducing the potential for acute infectious complications.

Regulatory References

  1. NIH MedlinePlus overview of Silver Sulfadiazine

Eligibility and Restrictions for Use

Who Can and Cannot Use Bentol? (Silver Sulfadiazine)

This section outlines the officially documented population eligibility and non-eligibility for Bentol, based strictly on government regulatory labeling. The medicine is primarily allowed for patients with second- and third-degree burn wounds.


Official Contraindications

Bentol must not be used in certain populations due to regulatory prohibitions:

  • Newborn Infants: Contraindicated in infants during the first 2 months of life and in premature infants.
  • Pregnancy: Contraindicated in pregnant women approaching or at term.
  • Hypersensitivity: Contraindicated in patients with known hypersensitivity to the active substance or any component of the cream.

Restrictions and Conditional Use

Specific conditions necessitate caution and patient monitoring when using Bentol:

  • Organ Function: Caution is required for patients with impaired renal function or impaired hepatic function (liver/kidney issues) as systemic absorption of the sulfonamide component may occur.
  • Metabolic Conditions: Use requires caution in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
  • Lactation: Use by nursing mothers requires a decision to discontinue either nursing or the drug itself.
  • Pediatric Use: Safety and effectiveness for children have not been fully established outside of the specific burn indication for those over two months of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bentol's official regulatory documentation identifies several categories of drugs and substances that may interact, primarily due to additive anticholinergic effects or synergistic inhibition of gastrointestinal movement.


Documented Interacting Medicines and Classes

The following categories and specific medicines are noted in official labeling for their potential to interact:

  • Anticholinergic Agents: Co-administration with other medicines having anticholinergic properties (e.g., certain antidepressants, antihistamines, or anti-Parkinson agents) may lead to an increase in additive effects.
  • Antiglaucoma Agents: Bentol may reduce the effectiveness of certain agents used to manage glaucoma and may increase intraocular pressure.
  • Agents Affecting Gastrointestinal Motility: Co-administration with drugs that inhibit gastrointestinal movement, such as pramlintide or glucagon, is documented as potentially increasing the risk of significant adverse gastrointestinal reactions.
  • Botulinum Toxin: Concurrent use may enhance the effects of the toxin, potentially leading to increased systemic anticholinergic effects and excessive weakness.
  • Antacids: The absorption of Bentol may be reduced when taken with antacids.

Interaction Constraints and Requirements

Official labeling contains specific requirements to manage these interactions. Use with pramlintide is contraindicated due to the high risk of severe inhibition of gastrointestinal motility. Prescribers are directed to avoid or use caution when combining Bentol with other anticholinergic-containing products or certain agents that affect the heart, such as Digoxin. The regulatory information may also state a need for specific timing requirements for discontinuation of Bentol before conducting certain diagnostic tests, such as secretin stimulation testing.

Mechanism of Action

The action of Bentol is achieved through two complementary mechanistic domains that target the signaling systems controlling gastrointestinal (GI) smooth muscle activity and secretion.


Antagonizing Parasympathetic Neurogenic Signals

This domain covers Bentol's primary interaction with Muscarinic Acetylcholine Receptors (mAChRs), particularly the M1, M2, and M3 subtypes, which are key components of the parasympathetic nervous system signaling cascade. By acting as an antagonist, Bentol blocks the binding of acetylcholine (ACh), thereby suppressing the nervous signal that normally triggers intestinal smooth muscle contraction and glandular secretion. This action initiates a myorelaxant cascade which results in decreased smooth muscle contraction.


Local Modulation of Spasmogenic Mediators

The mechanism is further reinforced by a secondary action where Bentol non-competitively inhibits the effects of local spasm-inducing chemicals such as histamine and bradykinin. These mediators are spasmogenic and promote muscle contraction. This domain modifies early molecular steps in the spasmodic pathway, resulting in modified gut wall tone and alters smooth muscle motility.

Dosage and Administration Information

Bentol: Official Administration Guidelines

Administration of Bentol (dicyclomine hydrochloride) involves specific routes, dosing, and procedural steps for adult patients. The medication is available in both oral and intramuscular (IM) forms.


Administration Details

Category Official Instruction (Adults)
Route of Administration Oral (capsules/tablets) or Intramuscular (IM) Injection only. Intravenous (IV) injection is strictly prohibited due to risk of thrombosis.
Initial Oral Dosing The recommended initial adult dose is 20 mg four times a day (QID).
Dose Escalation/Limit After one week, the dose may be increased to 40 mg QID. The total maximum recommended dose is 160 mg daily.
IM Use and Dosing IM injection is to be used only for 1 or 2 days when the patient cannot take oral medication. The recommended IM dose is 10 mg to 20 mg four times a day.

Procedural and Time Constraints

The dosage is adjusted according to individual patient response. All parenteral drug products must be visually inspected for particulate matter or discoloration prior to use.

Official Procedural Steps:

  • Oral Administration: Start with 20 mg QID. After one week, increase to 40 mg QID unless side effects prevent escalation.
  • IM Administration: For IM use, the syringe must be aspirated before injection to avoid inadvertent intravascular administration.
  • Discontinuation Rule: If clinical efficacy is not achieved within two weeks, or if side effects limit the dose below 80 mg per day, the drug should be discontinued.
  • Age-Specific Use: Documented safety data are not available for doses above 80 mg daily for periods longer than two weeks.

The official administration protocol outlines a stepwise approach for adults, starting with a scheduled oral dose that is assessed for efficacy and tolerance over a two-week period. The intramuscular route serves only as a strictly time-limited, temporary bridge when oral intake is compromised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bentol

Evidence for Use in Partial-Thickness (Second-Degree) Burns

Research exploring the effects of Bentol (Sulfadiazine Silver) on partial-thickness burn injuries primarily includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been used in research exploring how microbial patterns change over time, and they typically examined the compound’s classification as an anti-infective agent, along with outcomes related to physical discomfort. Researchers also monitored measurements of re-epithelialization, which is the time it takes for the wound surface to heal completely.

Studies reported measurements indicating a reduced presence of bacteria on the wound surface. However, when compared to other topical treatments and specialized dressings, findings were mixed. Some systematic reviews described patterns where re-epithelialization measurements were slower in those specific comparative studies. Research still provides limited context regarding its use against certain currently available topical options.

Evidence for Use in Full-Thickness (Third-Degree) Burns

The evidence base for Bentol in severe, full-thickness burns consists of clinical trials, often focused on complex, multi-component treatment protocols. In these settings, the research examined high-level outcomes related to systemic or functional imbalance, such as the reduction of microbial load and the risk of systemic infectious spread.

Studies report how microbial patterns evolved in the observed populations. The severity of third-degree burns requires comprehensive care; findings describing group patterns for systemic outcomes are often reflective of the entire treatment regimen rather than the specific patterns associated with Bentol in isolation. Research is still needed to clarify its isolated contribution to these complex care protocols.

What Remains Uncertain: Research Gaps and Inconsistency

The evidence highlights what is known—and what is still uncertain. A significant research limitation involves the mixed findings regarding wound healing time in partial-thickness burns compared to other available topical treatments. Additionally, the evidence quality varies across studies due to differences in trial design and patient populations.

There is limited information for long-term outcomes, meaning that the durability of microbial patterns and the lasting influence of the cream on final scar quality or appearance are not fully established by large-scale, long-duration trials. Research is still limited regarding patterns observed with Bentol across the entire pediatric population. Specific subgroup findings are uncertain for patients with severe kidney or liver impairment, where the systemic processing of the absorbed medicine may be altered.

Key Studies & References

  1. Silver Sulfadiazine (Topical Route) - NIH MedlinePlus
  2. Safety and Efficacy of Silver Sulfadiazine in the Management of Partial-Thickness Burns: A Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Bentol (FAQ)

Q: Can Bentol be used for long periods of time?

Official guidelines state that treatment is typically continued until the wound achieves satisfactory healing or is ready for grafting. Prolonged use is described in official information as potentially resulting in secondary fungal or bacterial infections (superinfection). Furthermore, some data indicates long-term use may slow the process of re-epithelization (new skin formation).

Q: Does Bentol require regular monitoring or tests while it is being used?

Official regulatory labels indicate that for patients with extensive burn wounds covering large body areas, monitoring may be necessary. This monitoring typically involves checking serum sulfa concentrations, evaluating renal function (kidney performance), and checking urine for the presence of sulfa crystals.

Q: Has Bentol been studied in women who are breastfeeding?

Official documents note that the drug's sulfonamide component is known to pass into human milk. Due to the potential for serious adverse reactions, such as kernicterus in the infant, the official labeling states that a decision must be made regarding whether to discontinue nursing or discontinue the use of the drug.

Q: What are the long-term potential safety themes associated with Bentol?

The official safety profile includes a rare but potential long-term effect called Argyria, which is a permanent bluish-gray discoloration of the skin. Studies examining long-term dermal toxicity in animals have not revealed evidence of carcinogenicity (the ability to cause cancer).

Q: Does Bentol have a Black Box Warning, and what does it relate to?

Official FDA labeling does not include a Black Box Warning. However, the label contains serious safety warnings related to the drug's sulfonamide component. These warnings reference the potential for rare but severe adverse reactions, such as life-threatening skin conditions (like Stevens-Johnson syndrome or Toxic Epidermal Necrolysis) and serious blood disorders (blood dyscrasias).

Q: What is the age limit for using Bentol?

The medication is strictly contraindicated (must not be used) in premature infants and in infants during the first two months of life. This is the official lower age limit restriction documented in regulatory documents. No upper age limit is specified in the official contraindications.

Q: How quickly does Bentol start to work after taking it?

The medication is described as an adjunct for the prevention and treatment of wound sepsis (infection). Official guidance relates the duration of use to the wound healing process, stating that treatment is typically continued until satisfactory healing has occurred or the wound is ready for grafting.

Q: What is the total time Bentol stays active in the body?

The active ingredient is a compound of silver and sulfadiazine. The sulfonamide component that can be absorbed systemically in certain conditions has a measured half-life of approximately 24 hours. The half-life refers to the time it takes for the amount of medicine in the body to be reduced by half.

Q: Are there any common foods or drinks that should be avoided when taking Bentol?

Official regulatory labeling does not provide a list of specific foods or drinks that must be avoided. Instead, official guidance states that the use of the medicine with food, alcohol, or tobacco should be discussed with a healthcare professional.

Q: Is it true that Bentol interacts with common over-the-counter pain relievers?

Yes, official interaction data indicates that interactions may occur between this medicine and common non-prescription pain relievers. This includes specific interactions with certain non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen.

Q: If I miss a dose of Bentol, what is generally recommended in official guidelines?

Official regulatory instructions for a missed dose state that the dose should be applied as soon as it is remembered. If it is almost time for the next scheduled application, the recommendation is to skip the missed dose and continue the regular schedule. Applying a double dose to make up for the missed one is generally not advised.

Q: Does Bentol carry a risk of dependence or addiction?

No. According to regulatory authorities, this medication is not classified as a controlled substance.

Q: Are there any studies looking at the use of Bentol in older adults?

Official regulatory documents indicate that there is currently no specific information available regarding the relationship of age to the effects of the drug in geriatric patients (older adults).

Q: Can Bentol be taken with common vitamins or supplements?

Yes, the official interaction profile includes potential interactions with common supplements and vitamins. This includes known interactions with both Vitamin C and Vitamin D.

Q: Does Bentol cause any noticeable changes to mood or behavior?

Although it is rare, official documents list Central Nervous System (CNS) dysfunction as a potential adverse reaction. CNS dysfunction refers to issues related to brain activity, which could impact mood or behavior.

Q: What should be done if a potential side effect is experienced while using Bentol?

Official patient guidance states that immediate medical help must be sought if severe or life-threatening symptoms, such as severe blistering, rash, or blood-related issues, are experienced. For non-serious or temporary symptoms like burning or itching, official instructions advise contacting a healthcare professional if the symptoms are persistent or bothersome.

Q: Do official documents mention anything about Bentol causing confusion or 'fogginess'?

Official adverse reaction reports list Central Nervous System (CNS) dysfunction as a potential, though rare, side effect. This classification includes potential cognitive changes, such as confusion or 'fogginess'.

Q: What is the usual recommended timeframe to see the full effect of Bentol?

The purpose of the medication is to prevent wound infection until satisfactory healing has occurred or the wound is ready for grafting. The total duration of therapy is therefore dependent upon the extent and severity of the burn wound being treated.

Q: What happens if Bentol is taken with alcohol?

Official regulatory labeling does not provide a specific warning about the consumption of alcohol. Instead, official guidance states that the use of the medicine in combination with alcohol should be discussed with a healthcare professional.

Q: Can Bentol be stopped suddenly?

Official guidance states that treatment is typically continued until the wound is healed or ready for grafting. The drug is generally not advised to be withdrawn while the possibility of infection remains, unless a significant adverse reaction occurs that requires immediate cessation.

Q: Are there different brand names that contain the active ingredient in Bentol?

Yes. The active ingredient, Silver Sulfadiazine, is available under multiple brand names. Commonly known examples include Silvadene, SSD, and Thermazene.

Q: Is Bentol a controlled substance?

No. The medication is not classified as a controlled substance by regulatory authorities.

Q: Are there known drug interactions between Bentol and common antibiotics?

Interactions are known to occur between this medication and other sulfonamides. Official documentation specifically references interactions with sulfonamide-containing antibiotics, such as those found in Bactrim.

Q: Are there any specific dietary requirements mentioned for patients taking Bentol?

Official regulatory labeling does not provide specific dietary requirements. Instead, official guidance states that the use of the medicine with food should be discussed with a healthcare professional.

Q: Are there any known interactions between Bentol and herbal products?

Official patient guidance states that informing a healthcare professional about all current medications, including natural products, herbal products, and vitamins, is generally recommended because interactions may occur.

How should Bentol be stored and disposed of?

How to Store and Dispose of Bentol? (Silver Sulfadiazine)

Official regulatory documents detail specific requirements for the storage and disposal of this medicine to maintain its stability and ensure safety.


️ Storage and Handling Conditions

Bentol cream must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The container should be kept tightly closed when not in use to protect the product. It is a regulatory mandate that the medicine be kept out of the sight and reach of children at all times.

️ Disposal of Unused Medicine

Unused or expired Bentol should be disposed of by taking it to an official medicine take-back program or designated collection site. If a take-back program is not available, the product must be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being placed in household trash. It is explicitly instructed not to flush this medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bentol found in:

A-Z Index: